Desentum
Phase 2Allergen immunotherapy that is effective, safe, patient-friendly and approved by the regulatory authorities.
Founded
2014
Focus
AntibodiesBiologics
About
Allergen immunotherapy that is effective, safe, patient-friendly and approved by the regulatory authorities.
Funding History
2Total raised: $15.8M
Series A$12MKurma PartnersApr 15, 2023
Seed$3.8MFinnish Industry InvestmentFeb 15, 2021
Company Info
TypePrivate
Founded2014
LocationHelsinki, Finland
StagePhase 2
Contact
SIMILAR COMPANIES
3PBIOVIAN
Pre-clinical · Turku
Faron Pharmaceuticals
Phase 1/2 · Turku
Finvector Vision Therapies
Pre-clinical · Kuopio
Bone Index
Pre-clinical · Kuopio
Genomill Health
Pre-clinical · Helsinki
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile